Antifungal drug resistance to azoles and polyenes

Lancet Infectious Diseases

Volumn 2, Issue 9, 2002, Pages 550-563

  Canuto, Mar Masiá ^a,b   Rodero, Félix Gutiérrez ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^b MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; AZITHROMYCIN; BENANOMICIN A; CASPOFUNGIN; COLONY STIMULATING FACTOR 1; CYTOKINE; FLUCONAZOLE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; ITRACONAZOLE; MICAFUNGIN; NIKKOMYCIN; POLYENE ANTIBIOTIC AGENT; POSACONAZOLE; PRADIMICIN A; PYRROLE DERIVATIVE; RAVUCONAZOLE; RIFAMPICIN; TRIAZOLE DERIVATIVE; TUMOR NECROSIS FACTOR; VORICONAZOLE;

ACUTE LEUKEMIA; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; CANDIDIASIS; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; IMMUNOTHERAPY; LIVER TOXICITY; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; VISUAL DISORDER;

EID: 0036724743     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00371-7     Document Type: Review

References (180)

1. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
2. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: Results of population-based laboratory active surveillance
3. Aspergillosis case-fatality rate: Systematic review of the literature
4. Amphotericin B: 30 Years of clinical experience
5. Treatment of systemic fungal infections with liposomal amphotericin B
6. Oral azole drugs as systemic antifungal therapy
7. Prophylactic oral fluconazole and candida fungaemia
8. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
9. Trends in antifungal use and antifungal isolates in a university hospital 1990-1992
10. An audit ofthe use of antifungal agents
11. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections
12. Correlation of fluconazole M1C and response to therapy for patients with candidemia due to C albicans and non-C albicans spp: Results of a multicenter prospective study ofcandidemia
13. In vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
14. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome of in a murine model of Aspergillus infection
15. Comparison of NCCLS and 3-(4,5-dimethyl-2-Thiazyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) methods of in vitro susceptibility testing of filamentous fungi and development of a new simplified method
16. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds
17. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
18. Emerging fungal pathogens: Evolving challenges to immunocompromised patients for the twenty-first century
19. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: A single institution experience over 10 years
20. Deep infections caused by Scedosporium prolificans. A report on 16 cases in Spain and a review of the literature
21. Resistance of Candida species to antifungal agents: Molecular mechanisms and clinical consequences
22. Present status of the detection of antifungal resistance: The perspective from both sides of the ocean
23. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome
24. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
25. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans
26. Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients
27. Point prevalence of oropharyngeal carriage of fluconazole-resistant Candida in human immunodeficiency virus-infected patients
28. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV infected patients
29. Epidemiology of yeast colonization and oropharyngeal infection other than Candida albicans in patients with HIV infection
30. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
31. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients
32. National nosocomial infectious surveillance system. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990
33. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
34. The epidemiology of hematogeneous candidiasis caused by different Candida species
35. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period
36. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program
37. Candida glabrata fungemia. Clinical features of 139 patients
38. International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
39. Estudio multicéntrico sobre funguemias por levaduras en España (abril-junio de 1997)
40. International surveillance of bloodstream infections due to Candida species: Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program
41. Importance of Candida species other than C. albicans as pathogens in oncology patients
42. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia
43. Candida krusei fungemia. An escalating serious infection in immunocompromised patients
44. Candida krusei fungemia. Report of 4 cases and review of the literature
45. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
46. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients
47. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management
48. Fatal disseminated infection with Aspergillus terreus in immunocompromised hosts
49. Practice guidelines for the treatment of candidiasis
50. The epidemiology of fusariosis in patients with haematological diseases. Gimema Infection Programme
51. In-vitro susceptibility of Aspergillus spp. isolates in vitro to amphotericin B and itraconazole
52. Invasive pulmonary aspergillosis due to Aspergillus terreus. 12-Year experience and review of the literature
53. Amphotericin B: Spectrum and resistance
54. Isolation and characterization of fluconazole-and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
55. Amphotericin B-resistant yeast infection in severely immunocompromised patients
56. Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: Analysis of aetiology risk factors and outcome
57. Disseminated candidiasis due to amphotericin B-resistant Candida albicans
58. Nosocomial fungemia due to amphotericin B-resistant Candida spp. in three pediatric patients after previous neurosurgery for brain tumors
59. Cross resistance to polyene and azole drugs in Cryptococcus neoformans
60. The effects of the polyene antibiotics nystatin and amphotericin B on thin lipid membranes
61. Chemistry and biology of the polyene macrolide antibiotics
62. Molecular mechanisms of drug resistance in fungi
63. Polyene-resistant mutants of Aspergillus fennelliae: Identification of sterols
64. 8,7 isomerase in a Cryptococcus neoformans strain from an AIDS patient
65. Incidence of polyene-resistant yeasts recovered from clinical specimens
66. Polyene resistance and the isolation of sterol mutants in Saccharomyces cerevisiae
67. Antimicrobial-drug resistance
68. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation
69. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double blind, multicenter trial
70. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis
71. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients
72. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles
73. Invasive infection due to Candida krusei in immunocompromised patients not treated with fluconazole
74. Candidemia in immunocompromised patients
75. Eight-year surveillance of non-albicans Candida spp. in an oncology department prior to and after fluconazole had been introduced into antifungal prophylaxis
76. Candidemia before and during the fluconazole era: Prevalence, type of species and approach to treatment in a tertiary care community hospital
77. Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
78. Clinical features of human infection with Scedosporium inflatum
79. The crisis in antibiotic resistance
80. Antibiotics that inhibit fungal cell wall development
81. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts
82. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cydophosphamide-induced immunosuppressed mice
83. Treatment of murine Candida krusei or Candida glabrata infection with L-743,872
84. Treatment of histoplasmosis with MK-991 (L-743,872)
85. Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii
86. A Randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis
87. A randomized, double-blind, multicenter study of caspofungin versus amphotericin B for the treatment of oropharyngeal and esophageal candidiasis
88. Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: A multicentre, randomized, double-blind study
89. Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B, AMB lipid formulations or azoles
90. Azole antifungal agents
91. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Antifungal activity and selectivity in vitro
92. A new triazole, voriconazole (UK-109,496), blocks sterol biosynthesis in Candida albicans and Candida krusei
93. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: Pharmacokinetics in man
94. Voriconazole: A new triazole antifungal
95. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp
96. In vitro testing of susceptibilities of filamentous ascomycetes to voriconazole, itraconazole, and amphotericin B, with consideration of phylogenetic implications
97. In vitro evaluation of voriconazole against clinical isolates of yeasts, moulds and dermatophytes in comparison with itraconazole, ketoconazole, amphotericin B and griseofulvin
98. In vitro activities of voriconazole, itraconazole, and amphotericin B against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma capsulatum
99. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi
100. Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia
101. UK 109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in acute invasive aspergillosis
102. UK 109,496, a novel, wide spectrum triazole derivative for the treatment of fungal infections: Clinical efficacy in chronic invasive aspergillosis
103. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole
104. Successful outcome of Scedosporium apiospermum disseminated infection treated with voriconazole in a patient receiving corticosteroid therapy
105. Open, randomised comparison of voriconazole and amphotericin B followed by other licensed antifungal therapy for primary therapy of invasive aspergillosis
106. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients
107. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
108. Effect of posaconazole on the pharmacokinetics of cyclosporine
109. In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole
110. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000
111. Safety and tolerance of posaconazole (SCH 56592) in patients with nonmeningeal disseminated coccidioidomycosis
112. Efficacy of SCH 56592 in treatment and prevention of invasive pulmonary aspergillosis in persistently neutropenic rabbits
113. An open, non-comparartive multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in then treatment of invasive fungal infections refractory to or intolerant to standard therapy
114. In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum
115. In vitro activity of a new oral triazole, BMS-207147 (ER-30346)
116. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections
117. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis
118. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
119. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia
120. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B
121. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: Maximum tolerated dose study
122. Zygomycosis in relapsed acute leukaemia
123. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis
124. In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus
125. Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis
126. Itraconazole solution: Higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis
127. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis
128. A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients
129. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS
130. Combined therapy with amphotericin B and 5-fluorocytosine for Candida meningitis
131. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis
132. Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models
133. Unusual etiology of visual loss in an HIV-infected patient due to endogenous endophthalmitis
134. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B
135. Amphotericin B with and without itraconazole for invasive aspergillosis: A three-year retrospective study
136. A randomized and blinded multicenter trial of high-dose fluconazole (F) + placebo (P) vs. F + amphotericin B (A) as treatment of candidemia in non-neutropenic patients
137. Synergistic effects of combination FK463 with amphotericin B: Enhanced efficacy in a murine model of invasive pulmonary aspergillosis
138. Caspofungin acetate: An antifungal agent
139. Combination therapy with caspofungin and amphotericin B lipid complex
140. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species
141. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy
142. Combination therapy in a model of pulmonary aspergillosis
143. Antifungal and surgical treatment of invasive aspergillosis: Review of 2,121 published cases
144. Combination antifungal therapy in treatment of murine pulmonary mucormycosis: Roles of quinolones and azoles
145. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis
146. Fluconazole plus cyclosporine: A fungicidal combination effective against experimental endocarditis due to Candida albicans
147. The exciting future of antifungal therapy
148. Adjunctive immune therapy for fungal infections
149. The potential role of cytokine therapy for fungal infections in patients with cancer: Is recovery from neutropenia all that is needed?
150. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus
151. Successful treatment of invasive aspergillosis in chronic granulomatous disease by granulocyte transfusions followed by peripheral blood stem cell transplantation
152. Phase I/II trial of neutrophil transfusions from donors stimulated with G-CSF and dexamethasone for treatment of patients with infections in hematopoietic stem cell transplantation
153. Amphotericin-B promotes leukocyte aggregation of nylon-wool-fiber-treated polymorphonuclear leukocytes
154. Does immune serum globulin confer protection against skin diseases?
155. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis
156. Antibody response that protects against disseminated candidiasis
157. Treatment of invasive pulmonary aspergillosis in severely neutropenic children with malignant disorders using liposomal amphotericin B (AmBisome), granulocyte colony-stimulating factor, and surgery: Report of five cases
158. Fungemia in patients with hematologic malignancies: Therapeutic effects of concomitant administration of fluconazole and granulocyte-colony-stimulating factor
159. Successful treatment of invasive thoracopulmonary mucormycosis in a patient with acute lymphoblastic leukemia
160. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients
161. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: Role of immune suppression
162. Antifungal effects of yeast-derived rhu-GM-CSF in patients receiving high-dose chemotherapy given with or without autologous stem cell transplantation: A retrospective analysis
163. Aspergillus vertebral osteomyelitis in a child with a primary monocyte killing defect: Response to GM-CSF therapy
164. Adjuvant therapy with rhGM-CSF for the treatment of Blastoschizomyces capitatus systemic infection in a patient with acute myeloid leukemia
165. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
166. Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer
167. Fatal haemoptysis associated with invasive pulmonary aspergillosis treated with high-dose amphotericin B and granulocyte-macrophage colony-stimulating factor (GM-CSF)
168. Immunorestitution disease involving the innate and adaptive response
169. Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor
170. Interferon-gamma in the management of chronic granulomatous disease
171. Tumor necrosis factor as an autocrine and paracrine signal controlling the macrophage secretory response to Candida albicans
172. Aspergillus fumigatus conidia induce a Th1-type cytokine response
173. Function associated with IL-2 receptor-beta on human neutrophils. Mechanism of activation of antifungal activity against Candida albicans by IL-2
174. Interleukin 12 as an adjuvant to Wl-1 adhesin immunization augments delayed-type hypersensitivity, shifts the subclass distribution of immunoglobulin G antibodies, and enhances protective immunity to Blastomyces dermatitidis infection
175. Cytokine treatment of central nervous system infection: Efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis
176. Interleukin-12 regulation of host defenses against Coccidioides immitis
177. Initiation of T-helper cell immunity to Candida albicans by IL-12: The role of neutrophils
178. Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT)